Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNCT19 in Relapsed or Refractory Autoimmune Neurological Diseases
NCT07275736Phase 1Recruiting
- Sponsor
- Juventas Cell Therapy Ltd.
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of inaticabtagene autoleucel in Neuromyelitis Optica Spectrum Disorder (NMOSD), myasthenia gravis (MG), Chronic inflammatory demyelinating polyradiculopathy (CIDP) and 3 more, sponsored by Juventas Cell Therapy Ltd. Primary endpoints: Number of participants with dose-limiting toxicities at 28 days and Number of participants with adverse events/serious adverse events at 36 months. Started Mar 2025; status: recruiting.
02
Drugs
inaticabtagene autoleucel
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)myasthenia gravis (MG)Chronic inflammatory demyelinating polyradiculopathy (CIDP)multiple sclerosis (MS)Autoimmune Encephalitis (AE)
Beyond the preview
Go deeper on NCT07275736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275736.